

JAN 31 2008

Application No. 10/530,106  
Amendment dated January 31, 2008  
Reply to Office Action of August 31, 2007

Docket No.: SLII-P01-003

**AMENDMENTS TO THE CLAIMS**

- 1.-15. (Cancelled)
16. (Currently Amended) A method to treat ~~or prevent~~ a src-associated cancer comprising administering to an individual a proteinaceous cross-linking agent capable of cross-linking at least two molecules of the protein tyrosine phosphatase Sap-1.
17. (Cancelled)
18. (Previously Presented) The method of claim 16, wherein the cancer is a gastrointestinal cancer.
19. (Previously Presented) The method of claim 18, wherein the gastrointestinal cancer is selected from the group consisting of esophageal tumor, stomach cancer, small-bowel tumor, large-bowel tumor, and pancreatic cancer.
20. (Canceled)
21. (Currently Amended) The method of claim 16 ~~20~~, wherein the proteinaceous cross-linker is an antibody directed against the extra-cellular domain of Sap-1.
22. (Previously Presented) The method of claim 21, wherein the antibody is directed against a Fibronectin-type III like domain of Sap-1.
23. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a monoclonal antibody.
24. (Currently Amended) The method of claim ~~claims~~ 21, wherein the cross-linking agent is a monoclonal antibody.

Application No. 10/530,106  
Amendment dated January 31, 2008  
Reply to Office Action of August 31, 2007

Docket No.: SLII-P01-003

25. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a humanized antibody.
26. (Currently Amended) The method of claim ~~claims~~ 21, wherein the cross-linking agent is a humanized antibody.
27. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a human antibody.
28. (Currently Amended) The method of claim ~~claims~~ 21, wherein the cross-linking agent is a human antibody.
29. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a soluble fragment of the extracellular domain of Sap-1.
30. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent comprises one, two, three, four, five, six, seven or eight Fibronectin-type III like repeats of Sap-1.
31. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is selected from the group consisting of: a mutein of the proteinaceous cross-linking agent, a fused protein of the proteinaceous cross-linking agent, a functional derivative of the proteinaceous cross-linking agent, an active fraction of the proteinaceous cross-linking agent, and salt of the proteinaceous cross-linking agent.
32. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a functional derivative of the proteinaceous cross-linking agent comprising at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.

Application No. 10/530,106  
Amendment dated January 31, 2008  
Reply to Office Action of August 31, 2007

Docket No.: SLII-P01-003

33. (Previously Presented) The method of claim 32, wherein the moiety is a polyethylene moiety.
34. (New) A method for inhibiting the catalytic activity of the protein tyrosine phosphatase Sap-1 in a cell, comprising administering to the cell a cross-linking agent capable of cross-linking at least two molecules of the Sap-1.
35. (New) The method of claim 34, wherein the cross-linking agent is a proteinaceous cross-linking agent.
36. (New) The method of claim 35, wherein the cross-linking agent is a monoclonal antibody.
37. (New) A method for inhibiting the activation of or deactivating c-src in a cell, comprising administering to the cell a cross-linking agent capable of cross-linking at least two molecules of the Sap-1.
38. (New) The method of claim 37, wherein the cross-linking agent is a proteinaceous cross-linking agent.
39. (New) The method of claim 38, wherein the cross-linking agent is a monoclonal antibody.